Thomas is co-founder, CEO, and a Board member of Oxular. He is an experienced and successful entrepreneur who has helped to build previous private-equity-backed ventures. He was formerly co-founder and CEO of ophthalmic pharmaceutical company Aciex Therapeutics, where he brought its lead program to NDA and led the company through a successful M&A exit. His prior professional history includes positions as both a company officer and a consultant working in operational and advisory roles related to capital raises, M&A transactions, industry consolidations, strategic planning, operations, debt financings, and post-merger integration.

Ronald is co-founder, Chief Scientific Officer, and a Board Observer of Oxular. With more than 30 years of medical device and drug product development experience, Ronald has led multi-disciplinary technical teams, clinical trial development, and product registration in the US, the EU, China, and Brazil. His ophthalmic experience includes the development of novel microcatheters for surgical treatment of glaucoma and retinal disease, sub-retinal delivery devices, diagnostic microspheres, and drug-releasing implants. Ronald’s technical background is in chemical engineering, biomaterials engineering, and biochemistry, and he is the inventor on more than forty granted patents related to medical products.

A board-certified neurologist and pharmacist, Friedrich is Oxular’s Chief Medical Officer and has over 20 years of experience in leading clinical and translational research in industry and academia. For more than a decade he has successfully headed clinical development programs in the US, Europe, and Asia. Friedrich was previously a key strategic contributor for retinal anti‑VEGF and other ophthalmic therapies at Bayer Pharma, including indications such as diabetic macular edema, diabetic retinopathy, and retinal vein occlusions. Friedrich previously worked on rare ophthalmic diseases at ProQR Therapeutics and as Senior Vice President of Clinical Development for an intravitreal cell therapy for Retinitis Pigmentosa at jCyte.

Marc is Oxular’s Senior Medical Advisor and a practicing vitreoretinal surgeon, with more than 30 years of experience in ophthalmic drug and medical device development. Previously, he was the National Eye Institute’s representative responsible for defining the clinical trial of Foscarnet, the first approved drug to treat CMV retinitis in AIDS patients. He initiated the use of Methotrexate for the treatment of intraocular lymphoma and intraocular tuberculosis. In collaboration with Thrombogenics, he was responsible for preclinical and clinical activities of Ocriplasmin, leading to the commercialization of Jetrea. Marc also participated in the launch of OTI’s transversal retinal OCT imaging, and the development of Preceyes BV’s tele-operated eye surgery robot.

Jatinder is Oxular’s Vice President of Quality. He has more than 25 years of experience in the quality assurance function, amassing extensive knowledge in the development and auditing processes of pharmaceuticals, including sterile injectables, oral dosage forms, and liquid suspension preparations, as well as medical devices. Jatinder has worked with several quality pharmaceutical companies, such as Novartis, Shire, and BTG, and has significant experience working with combination medical device and pharmaceutical products. He has overseen product technology transfers, designed and commissioned a sterile API plant, and established numerous quality management systems. He holds a PhD in Synthetic Organic Chemistry from Punjab University, India.

Ian is Oxular’s Vice President of Medical Device Development and Manufacturing. He has significant experience in all technical aspects of medical device development and high-volume medical product industrialization. Ian journeyed from aeronautical and broadcast engineering into medical technologies, where he has been involved in the design, development, and launch of products as varied as surgical robots, auto-injector combination solutions, and stoma appliances. He is adept at building product development and industrialization teams capable of creating innovative new products and bringing them successfully to market. Prior to joining Oxular, Ian was Managing Director at Eakin Surgical, where he was responsible for the creation of a contract development and manufacturing organization function.

Pamela is Oxular’s Senior Director of Regulatory Affairs, with over 30 years of experience working in all aspects of regulatory strategy and submissions. Previously, Pamela managed and coordinated regulatory efforts at Genocea, ProMedDx and Ximedica. She has significant experience in regulatory development, strategy, and filings and brings technical experience in clinical trials design, chemistry, manufacturing, and controls and has led regulatory efforts for projects that combined novel drugs with biologic delivery devices. Additionally, Human Factor Engineering strategies for investigational drugs, biologics, medical devices, and combination products. Pamela’s industry background includes oncology, pharmacology, pharmacokinetics, and antigen-specific targeted therapeutics, as well as adoptive cell therapies and gene therapies.

Chris is Oxular’s Vice President of GMP Drug Manufacturing, with more than 25 years of industry experience. Chris’s experience spans chemistry, manufacturing, and manufacturing controls, pilot-to-full scale production project management in both APIs and finished product, alliance management, injectable product development, formulation development, process development and scale-up, and licensing and partnering. He has also authored or contributed to over 70 patents, publications, and presentations concerning project management, business, and pharmaceutical development. Chris received a BS in Chemistry and an MBA from the University of Albany, USA, and holds a PhD in Synthetic Organic Chemistry from the University of New Hampshire, USA.

Stacey is Oxular’s Finance Director since 2018 and brings significant knowledge and experience in all aspects of finance, administration, and human resources involved with managing a biotech start-up.  Stacey provides cross-functional leadership and operational oversight, manages the entire finance function, including support of business financings, and investor and board relations. Stacey also coordinates information technology and accounting systems, insurance programs, and technology grant applications. She previously led finance and operations teams in several industries, including publishing and aviation; notably, while at aviation company Hangar8, she led a public listing and reverse takeover with Gama Aviation. Stacey is a qualified accountant.